Two pneumonia vaccines, Meshadong and Pfizer, are in short supply in the European market

(2020/10/26) A brief history of Chinese doctors" flying knives: whether doctors are free or unit people; (Click on the title, available in the original) "Pharmaceutical 1st Time" Mercedon, Pfizer 2 pneumonia vaccine in the European market is in short supply of the global new crown pneumonia COVID-19 outbreak continues to rage, winter is approaching, the European Union market already has two major pneumococcal vaccine shortage, health regulators have begun to worry about the new coronavirus, pneumonia and seasonal influenza may appear together, resulting in a new wave of outbreaks.
: The surge in demand for vaccines has put supplies at merca East and Pfizer on high alert.
history of Chinese doctors flying knives: Are doctors free or unit people? The Medical Practitioners Act of 1999 established the registration system of physicians in China, and also tied doctors to public hospitals.
the huge economic benefits brought about by the serious imbalance of medical resources, the "flying knife" wind is becoming more and more serious.
the next 20 years, surgeons, hospital chiefs and policymakers, have been engaged in a long tug-of-war.
headlines: Where is the path of free practice for Chinese doctors going to go? Where is the surge in new drug licensing transactions in China? Where is the "crossroads" for innovative pharmaceutical companies? In the first eight months of this year, Chinese biotech companies outsourced a surge in licensing transactions, reflecting the growing number of local Chinese biotech companies with innovative capabilities and high-quality products contributing to the global market.
102 of the 189 biopharmaceutical deals that took place in the first eight months of this year were licensing and cooperative transactions, and 44 were outsourced licensing transactions by companies from China.
: Where does the licensing trend come from? Firestone Creation: The Yangtze River Delta biopharmaceutical industry policy research Yangtze River Delta region biopharmaceutical industry development in the national leading position, in which policy support in the Yangtze River Delta biopharmaceutical industry in the convergence, integration and high-quality innovation and development played an important role.
: Deepening industrial development in the future needs to break down administrative barriers and work together.